Evaluating the Potential Use of GcMAF in Treating Metastatic Goblet Cell Adenocarcinoma with Peritoneal Malignancy: Current Research and Considerations
Question today: will Gcmaf be useful in a case of appendiceal cancer— specifically, goblet cell Adenocarcinoma that has metastasized locally to the peritoneum (peritoneal malignancy)? Extensive research suggesting standard systemic chemotherapy is not curative with these patients because of the peritoneal-plasma barrier; chemo is not able to get directly to the peritoneal nodules thus, it’s effects are significantly reduced.. So we’re curious if you have resources explaining GC MAF pathways and how it gets to the peritoneum and if so, what the efficacy has been so far? Answer from me: This is an interesting and unusual type of cancer. I refer to Goblet cell adenocarcinoms. It often metastasizes to the peritoneal cavity. The peritoneal cavity is a dangerous topography. Though it's not an organ itself, great caution must be taken to not cause any amount of peritoneal inflamatory effect. It can be more dangerous for inflammation here than any other organ. I have gone through thousands of files on my extensive database, but I can not find anything sufficient to give advice based on my database. There have not been studies on this type of Cancer andgcmaf, this is due to the rareness of the type of cancer. I can not advise you based on my personal opinion or theory, I have nothing scientific to back anything. I would never rely on the option of anyone without real science and previous research case history. These are not available to date. I do have a wide understanding of this rare form. I just don't have gcmaf studies to date.
GcMAF #GobletCellAdenocarcinoma #PeritonealMalignancy #CancerResearch #OncologyScience